Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveals differences in efficacy and drug resistance development
MEK1/2 抑制剂治疗 2 型神经纤维瘤病相关神经鞘瘤的临床前评估揭示了疗效和耐药性发展的差异
期刊:Neuro-Oncology
影响因子:16.4
doi:10.1093/neuonc/noz002
Marisa A Fuse, Christine T Dinh, Jeremie Vitte, Joanna Kirkpatrick, Thomas Mindos, Stephani Klingeman Plati, Juan I Young, Jie Huang, Annemarie Carlstedt, Maria Clara Franco, Konstantin Brnjos, Jackson Nagamoto, Alejandra M Petrilli, Alicja J Copik, Julia N Soulakova, Olena Bracho, Denise Yan, Rahul